263 related articles for article (PubMed ID: 30738371)
1. High and low on-treatment platelet reactivity to P2Y
Ferreiro JL; Vivas D; De La Hera JM; Marcano AL; Lugo LM; Gómez-Polo JC; Silva I; Tello-Montoliu A; Marín F; Roldán I
Thromb Res; 2019 Mar; 175():95-101. PubMed ID: 30738371
[TBL] [Abstract][Full Text] [Related]
2. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
[TBL] [Abstract][Full Text] [Related]
3. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome.
Bonello L; Laine M; Camoin-Jau L; Noirot F; Guieu R; Dignat-George F; Paganelli F; Frere C
Thromb Haemost; 2015 Oct; 114(4):702-7. PubMed ID: 26311415
[TBL] [Abstract][Full Text] [Related]
4. Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes.
Joshi RR; Hossain R; Morton AC; Ecob R; Judge HM; Wales C; Walker JV; Karunakaran A; Storey RF
Platelets; 2014; 25(6):416-22. PubMed ID: 24111601
[TBL] [Abstract][Full Text] [Related]
5. Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction.
Kerneis M; Silvain J; Abtan J; Hauguel M; Barthélémy O; Payot L; Brugier D; Galier S; Collet JP; Montalescot G
Arch Cardiovasc Dis; 2015 Oct; 108(10):502-10. PubMed ID: 26113480
[TBL] [Abstract][Full Text] [Related]
6. P2Y
Ortega-Paz L; Bor W; Franchi F; van den Broek WWA; Rollini F; Giordano S; Galli M; Been L; Ghanem G; Shalhoub A; Garabedian H; Al Saleh T; Uzunoglu E; Zhou X; Rivas A; Pineda AM; Suryadevara S; Soffer D; Mahowald MK; Choi CY; Zenni MM; Phoenix F; Ajjan RA; Ten Berg JM; Angiolillo DJ
JACC Cardiovasc Interv; 2024 Jun; 17(11):1356-1370. PubMed ID: 38597172
[TBL] [Abstract][Full Text] [Related]
7. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
Aradi D; Tornyos A; Pintér T; Vorobcsuk A; Kónyi A; Faluközy J; Veress G; Magyari B; Horváth IG; Komócsi A
J Am Coll Cardiol; 2014 Mar; 63(11):1061-70. PubMed ID: 24486281
[TBL] [Abstract][Full Text] [Related]
8. Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational study.
Alexopoulos D; Vogiatzi C; Stavrou K; Vlassopoulou N; Perperis A; Pentara I; Xanthopoulou I
Cardiovasc Diabetol; 2015 May; 14():68. PubMed ID: 26025572
[TBL] [Abstract][Full Text] [Related]
9. A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients.
Straub N; Beivers A; Lenk E; Aradi D; Sibbing D
Thromb Haemost; 2014 Feb; 111(2):290-9. PubMed ID: 24154566
[TBL] [Abstract][Full Text] [Related]
10. Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes.
Koshy AN; Giustino G; Sartori S; Hooda A; Feng Y; Snyder C; Dasgupta S; Kumar KR; Krishnamoorthy-Melarcode P; Sweeny J; Khera S; Serrao GW; Sharma R; Dangas G; Kini AS; Mehran R; Sharma SK
EuroIntervention; 2023 Mar; 18(15):1244-1253. PubMed ID: 36660810
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction.
Lee YS; Jin CD; Kim MH; Guo LZ; Cho YR; Park K; Park JS; Park TH; Kim YD
Circ J; 2015; 79(6):1248-54. PubMed ID: 25959558
[TBL] [Abstract][Full Text] [Related]
12. Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. A pharmacodynamic randomised study.
Laine M; Frère C; Toesca R; Berbis J; Barnay P; Pansieri M; Michelet P; Bessereau J; Camilleri E; Ronsin O; Helal O; Paganelli F; Dignat-George F; Bonello L
Thromb Haemost; 2014 Feb; 111(2):273-8. PubMed ID: 24154787
[TBL] [Abstract][Full Text] [Related]
13. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
Gurbel PA; Bliden KP; Logan DK; Kereiakes DJ; Lasseter KC; White A; Angiolillo DJ; Nolin TD; Maa JF; Bailey WL; Jakubowski JA; Ojeh CK; Jeong YH; Tantry US; Baker BA
J Am Coll Cardiol; 2013 Aug; 62(6):505-12. PubMed ID: 23602770
[TBL] [Abstract][Full Text] [Related]
14. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
[TBL] [Abstract][Full Text] [Related]
15. Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention.
Laine M; Toesca R; Berbis J; Frere C; Barnay P; Pansieri M; Peyre JP; Michelet P; Bessereau J; Camilleri E; Helaf O; Camaleonte M; Paganelli F; Dignat-George F; Bonello L
Thromb Res; 2013 Jul; 132(1):e15-8. PubMed ID: 23726090
[TBL] [Abstract][Full Text] [Related]
16. A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Dasbiswas A; Rao MS; Babu PR; Vijayvergiya R; Nayak R; Dani S; Tyagi S; Hiremath S; Patel T; Alexander T; Prakash VS; Singh DP; Yadav MK; Pathak K; Srivastava A
J Assoc Physicians India; 2013 Feb; 61(2):114-6, 126. PubMed ID: 24471250
[TBL] [Abstract][Full Text] [Related]
17. Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Uhry S; Bessereau J; Camoin-Jau L; Paganelli F; Bonello L
Hosp Pract (1995); 2012 Apr; 40(2):104-17. PubMed ID: 22615085
[TBL] [Abstract][Full Text] [Related]
18. Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial.
Diodati JG; Saucedo JF; Cardillo TE; Jakubowski JA; Henneges C; Effron MB; Lipkin FR; Walker JR; Duvvuru S; Sundseth SS; Fisher HN; Angiolillo DJ
Thromb Haemost; 2014 Aug; 112(2):311-22. PubMed ID: 24718367
[TBL] [Abstract][Full Text] [Related]
19. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
20. Comparison of P2Y12 receptor inhibition by clopidogrel and prasugrel in patients undergoing percutaneous coronary intervention.
Haq MM; Ahsan CH; Amin MN; Karim MR; Ali ML; Khan SR; Chowdhury MZ; Mansur M; Millat MH; Rashid MA
Bangladesh Med Res Counc Bull; 2013 Dec; 39(3):139-45. PubMed ID: 26118162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
